Herbert Smith Freehills (HSF) and Latham & Watkins won lead roles on Baxter International’s acquisition of Claris Injectables for $625m, in a bid by Baxter to expand its portfolio of essential generic injectable medicines. HSF represented Claris, while Latham acted for Baxter.
Your limit of 1 article in 30 days is up. Please login for full access or subscribe.
Corporate users - click here for simple access (no password needed).
For more information, please contact [email protected]
